What Glemont L Treats: Main Uses and Benefits

Glemont L is commonly used in situations involving certain distressing symptoms across conditions where symptoms may intensify temporarily across multiple therapeutic domains.

Dual Relief for Persistent Allergic Rhinitis and Hay Fever

This medication is relevant in contexts where additional symptomatic support is needed for allergic rhinitis, encompassing both seasonal (hay fever) and perennial (year-round) forms. It helps address symptom clusters that may become intense or disruptive, such as nasal congestion, sneezing, runny nose, itchy eyes, wheezing, coughing, and persistent skin itching. This provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

---

Long-Term Support for Chronic Respiratory and Skin Inflammation

Glemont L is relevant in conditions characterized by periods of heightened symptoms of asthma, where it may be part of symptomatic management as an add-on therapy. It is applied in addressing chronic inflammatory symptoms that create noticeable physiological strain. It may assist with managing symptoms associated with exercise-induced bronchoconstriction, easing the impact of symptoms on routine activities. This combination is also considered relevant for managing symptoms that interfere with daily comfort, specifically the uncomplicated skin manifestations of chronic hives (urticaria).

---

Quick Fact: Relief for Dual Airway Distress
Primary Focus	Managing symptoms of Allergic Rhinitis and Asthma.
Symptom Scope	Upper airway, lower airway, and skin manifestations.
Context of Use	Long-term support for chronic and recurrent symptoms.
Benefit	Helps ease overall symptom load and supports comfort.

Regulatory References

1. Philippine FDA Document

Glemont L, a combination of Montelukast and Levocetirizine, is typically used for managing chronic allergic conditions such as seasonal and perennial allergic rhinitis, as well as rhinitis associated with asthma.

Who Can Use Glemont L?

This medication is generally prescribed for adults and children of a specific age as determined by a healthcare provider. It is used for the long-term control and prevention of symptoms. Dosage and appropriateness for use in patients with conditions like mild-to-moderate liver or kidney impairment must be individually assessed by a physician.

Who Cannot Use Glemont L?

Glemont L is contraindicated in certain patient groups to ensure safety. Do not use this medicine if you have:

• Known Hypersensitivity: An allergy to Montelukast, Levocetirizine, Cetirizine, or any other component listed in the formulation.
• Severe Kidney Impairment: This is a major contraindication due to how Levocetirizine is processed and eliminated from the body.
• Acute Asthma Attack: This medicine is not a rescue inhaler and should not be used to treat a sudden, severe asthma exacerbation.
• Rare Hereditary Disorders: Patients with hereditary problems like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medication, as it often contains lactose.

Patients with a history of mental health problems or those who develop any neuropsychiatric symptoms (e.g., agitation, depression, suicidal thoughts) while on this medication must inform their doctor immediately. Caution is also advised for use during pregnancy and breastfeeding, where the potential benefits must outweigh the risks.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Glemont L (Levocetirizine/Montelukast) as classified by regulatory authorities.

---

Interaction-Related Restrictions

The medicine is contraindicated in patients diagnosed with severe renal impairment, defined as a Creatinine Clearance less than 10 mL/min, due to the dependence of Levocetirizine's clearance on kidney function. Caution is also advised in patients with impaired hepatic function because Montelukast is eliminated primarily through bile.

---

Pharmacokinetic and Pharmacodynamic Interactions

Hepatic Enzyme Modulators: Co-administration with potent hepatic enzyme inducers, such as Phenobarbital or Rifampicin, can officially reduce the systemic exposure (AUC) of Montelukast. Conversely, the agent Gemfibrozil may increase Montelukast exposure by inhibiting the CYP 2C8 enzyme. The agent Ritonavir is documented to increase the plasma AUC and decrease the clearance of the Levocetirizine component.

CNS Depressants: Co-administration with alcohol or other CNS depressants is documented to cause an additive impairment of CNS performance and a reduction in alertness. Food does not affect the total extent of Levocetirizine absorption but decreases the rate of absorption. Patients with known aspirin sensitivity should continue avoidance of NSAIDs or aspirin.

Dual Blockade of Inflammatory Signals

The mechanism involves a coordinated intervention across two distinct chemical pathways central to inflammation. The mechanism involves the interaction with the Histamine H1-receptor ( H1 R) and the Cysteinyl Leukotriene Type 1 Receptor ( CysLT1 Receptor). This dual action modulates the inflammatory signaling cascade by limiting the functional consequences of both histamine (an amine mediator) and leukotrienes (lipid mediators).

---

Modulation of H1 R-Mediated Vascular and Neural Signaling

The H1 R interaction is the primary mechanistic domain influencing acute physiological changes. By acting as an inverse agonist/antagonist, the drug limits the histamine-induced cascade that typically leads to increased vascular permeability and stimulation of peripheral sensory nerves. This H1 R mechanistic effect reduces the cascade resulting in increased fluid leakage and sensory nerve firing within the neurovascular system.

---

Blockade of CysLT1-Driven Cellular and Contractile Responses

The CysLT1 receptor mechanism primarily influences sustained inflammatory responses. Montelukast blocks this receptor, preventing the potent effects of leukotrienes that drive smooth muscle contraction and the recruitment and infiltration of inflammatory cells, such as eosinophils, into mucosal tissues. This interruption of the leukotriene pathway results in the modulation of tissue-level fluid accumulation and smooth muscle tone within the airways and nasal passages.

How to Use Glemont L

This section details the usage and administration principles for Glemont L.

---

Administration Scope

Feature	Guideline
Route of Administration	The medicine is administered through the oral route only.
Dosing Schedule	The standard regimen for adults and adolescents 15 years of age and older is one film-coated tablet (Montelukast 10 mg / Levocetirizine 5 mg) per day.
Timing in relation to meals	The tablet may be taken with or without food.
Preparation Requirements	The dose must be swallowed whole with liquid and should not be crushed, chewed, or split.
Special Procedural Conditions	Administration is typically advised to occur in the evening.

---

Population and Contextual Rules

Feature	Guideline
Age-Group Rules	The specific 10 mg/5 mg fixed-dose combination strength is generally not recommended for children and younger adolescents.
Dose Adjustment	Dosing interval modification is required for patients diagnosed with moderate to severe renal impairment; no adjustment is typically needed for mild to moderate hepatic impairment.
Use-Context Constraints	The medicine must not be used for the treatment of acute asthma attacks (bronchospasm); it is designated for maintenance therapy only.

---

Final Procedural Structure

The guidelines establish a standardized once-daily oral regimen. This protocol dictates that the specific tablet strength is to be taken whole in the evening, irrespective of food intake. The use is for maintenance, and the instructions outline necessary dosing interval adjustments for adherence in the context of impaired kidney function.

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored how the agent may affect inflammation. Studies have investigated whether the agent may be associated with reduced progression of joint damage.

Studies have examined the agent’s effects on symptoms such as pain and swelling. Research has investigated whether the agent may be associated with slowing the rate of joint destruction.

Clinical trials have reported varying timelines for when participants experienced changes, with some studies focusing on outcomes at 12 weeks of treatment. Evidence has been evaluated to determine if this agent is associated with long-term symptom management.

---

Evaluation in Combination with Methotrexate (MTX)

Clinical research has frequently evaluated the use of this agent in combination with Methotrexate (MTX). Studies have investigated whether the use of this agent in combination therapy results in different anti-inflammatory responses.

Research has examined differences in the time to onset of change and the duration of pain management reported by participants receiving combination therapy.

---

Research on Use in Other Conditions

Research has also explored the agent's effects on symptoms associated with Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS). Studies examined whether the agent's actions may be associated with slowing the progression of spine and joint changes in AS patients.

Key Studies & References

1. Biologics for treating moderate rheumatoid arthritis (NICE Technology Appraisal Guidance - Representative Clinical Guideline)

Common questions about Glemont L (FAQ)

Q: How quickly should I feel better after starting Glemont L?

A: Official information indicates that the active components in Glemont L are designed to work quickly. The Montelukast component reaches its maximum concentration in the blood within approximately 3 to 4 hours after taking a dose, and the Levocetirizine component reaches its peak around one hour.

Q: Is Glemont L the same as just taking a standard allergy pill?

A: No, Glemont L is a fixed-dose combination of two different types of medicine. It contains Levocetirizine, a second-generation H1-antagonist (the component found in standard allergy pills), and Montelukast, a Leukotriene Receptor Antagonist. This provides a coordinated, dual anti-inflammatory action.

Q: What's the difference between Glemont L and Zyrtec (cetirizine)?

A: The Levocetirizine component in Glemont L is the active form of Cetirizine ( Zyrtec). Glemont L combines this active antihistamine with Montelukast (a Leukotriene Receptor Antagonist), while Zyrtec is a single-ingredient medicine.

Q: Has Glemont L been studied in children under the age of 12?

A: The specific 10 mg/5 mg fixed-dose combination strength of Glemont L is not typically recommended for children and younger adolescents. Regulatory labeling for the individual components does include use in children for certain indications, but only in appropriate lower-strength, single-agent formulations.

Q: Is it normal to feel a bit tired when first starting Glemont L?

A: Yes, somnolence (drowsiness) and fatigue are officially listed as common side effects associated with this medication. Official information also notes that the risk of somnolence (drowsiness) may be more apparent when treatment is initiated.

Q: Does taking Glemont L affect blood test results?

A: Official product information lists that certain abnormalities have been reported from clinical studies. These include elevated levels of liver enzymes ( ALT, AST), and rare reports of thrombocytopenia (a low platelet count).

Q: Are there any foods or drinks I should avoid while on Glemont L?

A: The official labeling documents a clinically relevant interaction with alcohol. Combining Glemont L with alcohol can cause an additive impairment of central nervous system (CNS) performance and a reduction in alertness.

Q: How long does Glemont L stay in your system?

A: The Montelukast component has a mean plasma half-life (the time it takes for half the drug to be cleared) ranging from 2.7 to 5.5 hours. The Levocetirizine component has a half-life of approximately 7 to 10 hours. This indicates that the medicine is primarily eliminated from the body within approximately 24 hours.

Q: Can Glemont L help with hives or just seasonal allergies?

A: Official documentation indicates the medicine is used for both. The Levocetirizine component is specifically indicated for treating the symptoms associated with chronic idiopathic urticaria (hives), as well as seasonal and perennial allergic rhinitis.

Q: Is Glemont L considered a steroid medication?

A: No. According to official product labeling, Glemont L is classified as a Leukotriene Receptor Antagonist ( LTRA) and a Second-Generation H1 -Antagonist (antihistamine). It is not a steroid.

Q: Are there reported long-term side effects from taking Glemont L?

A: Regulatory documents list a range of adverse reactions reported both from clinical trials and post-marketing experience. This includes rare but serious neuropsychiatric events like suicidal thoughts, aggression, and mood changes. Patients are encouraged to be aware of any new or worsening mood or behavioral symptoms and report them to a healthcare professional.

Q: What should I do if I accidentally miss a dose of Glemont L?

A: Official patient information outlines a procedure for a missed dose: if a dose is missed, it can be taken when remembered. However, if it is nearly time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is resumed. Taking two doses together to compensate for a missed dose is generally not advised.

Q: Can Glemont L be used for non-allergic conditions?

A: The medicine is specifically indicated in regulatory documents for conditions rooted in allergic and inflammatory processes, such as seasonal and perennial allergic rhinitis and asthma (maintenance treatment). Official documents do not list non-allergic conditions as approved indications for use.

Q: What are the main benefits of Glemont L for asthma patients?

A: The Montelukast component of Glemont L is indicated in regulatory documents for the prophylaxis (prevention) and chronic treatment of asthma. It is specifically designated for maintenance therapy and is not intended to treat sudden, severe asthma attacks.

Q: Is there a generic version of Glemont L available?

A: Glemont L is a brand-name medicine. Its two active ingredients, Montelukast and Levocetirizine, are available as generics. The availability of a fixed-dose combination (FDC) generic version depends on specific regulatory approvals.

Q: Can Glemont L make my anxiety worse?

A: Yes, regulatory information documents anxiety, agitation, and other neuropsychiatric events as uncommon to rare side effects, primarily associated with the Montelukast component. Patients are advised to look out for any new or worsening mood symptoms.

Q: What happens if you stop taking Glemont L suddenly?

A: The medicine is intended for chronic maintenance therapy. For patients using it to manage asthma, stopping suddenly may lead to a worsening of respiratory symptoms. It is important that patients do not discontinue this medicine without consulting their prescriber.

Q: Is Glemont L safe for use in older adults (seniors)?

A: The use of Glemont L in older adults requires caution. This is primarily due to the potential for greater somnolence (drowsiness) and the increased likelihood of reduced kidney function, which necessitates dose adjustments for the Levocetirizine component.

Q: Does Glemont L affect your ability to drive or operate machinery?

A: The medicine is generally not expected to affect driving, but regulatory information advises that some individuals have reported drowsiness or dizziness. Individuals should observe how they respond to the medication before engaging in activities that require full mental alertness.

Q: Are there any less common, but serious side effects of Glemont L I should know about?

A: Yes, serious but rare side effects include suicidal ideation and behavior, aggression, hallucinations, and severe allergic reactions like anaphylaxis. It is necessary to seek immediate medical advice if any of these serious symptoms occur.

Q: Is Glemont L effective against all types of allergy triggers?

A: Official information states that the medicine is indicated for seasonal and perennial allergic rhinitis, which addresses a broad range of environmental and inhaled allergens. Its effectiveness is tied to its mechanism of action on H1 R and CysLT1 receptors, which mediate allergic and inflammatory responses.

Q: Can I take Glemont L if I am planning to get pregnant soon?

A: Official labeling advises that as a precautionary measure, it is preferable to avoid the use of the individual components ( Levocetirizine and Montelukast) during pregnancy. The decision to use it requires a determination by a healthcare provider regarding the potential benefits versus the risks.

Q: Do studies show Glemont L is better than a placebo?

A: Clinical trial data that supports the efficacy and use of the drug is referenced in regulatory documents. The dual-action combination has demonstrated a benefit in managing symptoms compared to an inactive substance ( placebo) in studies.

Q: Is Glemont L known to interact with birth control pills?

A: Drug interaction studies with the Montelukast component, when co-administered with oral contraceptives ( ethinyl estradiol/norethindrone), have not shown clinically important effects on the pharmacokinetics of the contraceptive.

Q: Why is Glemont L sometimes used off-season, not just during allergy season?

A: The medicine is indicated for both seasonal allergic rhinitis and perennial allergic rhinitis, which accounts for year-round symptoms (used 'off-season'). It is also indicated for the chronic treatment of asthma.

Q: Does Glemont L help with congestion or mainly just sneezing and itching?

A: The dual classification as an antihistamine and Leukotriene Receptor Antagonist is designed to manage a wide spectrum of allergic symptoms. This includes nasal congestion, which is a key symptom of allergic rhinitis (the primary indication) that is often driven by leukotriene activity.

Q: What is the typical duration of treatment with Glemont L?

A: The medicine is indicated for the chronic treatment and prophylaxis of conditions like asthma and perennial allergic rhinitis. This implies long-term maintenance use, but the specific duration is determined by a healthcare provider.

Q: Does Glemont L cause headaches?

A: Yes, headache is officially listed in regulatory documents as a common side effect reported in clinical studies.

Q: Is Glemont L ever used for cold symptoms?

A: No. The medicine is indicated for managing chronic allergic conditions ( allergic rhinitis and asthma). It is not indicated for the temporary relief of symptoms associated with the common cold.

Q: Where can I find reliable, official information about Glemont L research?

A: Authoritative clinical research and evidence used for the medicine's approval can be found in the Clinical Studies section of the FDA Prescribing Information and the Summary of Product Characteristics (SmPC) published by various regulatory agencies.

Q: Why is Glemont L often mentioned for chronic urticaria (hives)?

A: The Levocetirizine component is specifically indicated in regulatory documents for the treatment of symptoms associated with chronic idiopathic urticaria (hives), making it an officially approved use for this condition.

How to Store and Dispose of Glemont L

This information details the storage and disposal requirements for Glemont L (Montelukast Sodium and Levocetirizine Dihydrochloride) film-coated tablets, as specified in regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store below 30°C (Room temperature).
Protection	Must be protected from light and moisture.
Container	Store in the original container or package.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired product must follow official guidelines. The medicine must not be disposed of via wastewater or household waste. Unused Glemont L should be disposed of according to local regulations for pharmaceutical waste. Patients are advised to ask their pharmacist for instructions on how to properly discard the medicine.